A. S. Anderson

Preclinical Characterization of the Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine

The monovalent Omicron XBB.1.5-adapted BNT162b2 mRNA vaccine elicits stronger neutralizing antibody responses against XBB.1.5 and related sublineages than the bivalent Wild Type + Omicron BA.4/5 vaccine.

Intrinsic and extrinsic factors regulate FtsZ function in Caulobacter crescentus

This study investigates how intrinsic and extrinsic factors regulate FtsZ function in Caulobacter crescentus, revealing roles for GTP hydrolysis, the C-terminal linker, and FtsA in Z-ring dynamics and cell division.

Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine

This study compares the neutralizing antibody responses induced by monovalent and bivalent BA.4/5 vaccines against multiple Omicron sublineages in individuals over 55 years old, finding the bivalent vaccine elicits stronger neutralization.

Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent in vitro activity against the SARS-CoV-2 Omicron variant

This study evaluates the antiviral activity of nirmatrelvir, molnupiravir, and remdesivir against the SARS-CoV-2 Omicron variant and confirms their potency.

Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of Concern

This paper evaluates the antiviral activity of Nirmatrelvir against multiple SARS-CoV-2 variants using qRT-PCR in VeroE6 cells, showing potent inhibition across all tested variants.

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19

This study identifies PF-00835321 as a potent inhibitor of SARS-CoV-2 3CL protease with in vitro antiviral activity and clinical evaluation potential.